Article
Multidisciplinary Sciences
Xiaorong Zhou, Chenchen Li, Zhao Zhang, Daniel Y. Li, Jinwei Du, Ping Ding, Haiyan Meng, Hui Xu, Ronglei Li, Effie Ho, Aiguo Zhang, Paul Okunieff, Jianwei Lu, Michael Y. Sha
Summary: This study evaluates the utility of plasma cell-free DNA (cfDNA) as a prognostic biomarker and efficacy predictor of chemotherapy in NSCLC patients. The findings show that baseline cfDNA positively correlates with tumor burden, while cfDNA kinetics can distinguish responsive individuals from non-responsive ones. Additionally, cfDNA Ratio has predictive value in patients with chemotherapy plus VEGFIs.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Niklas Kluemper, Jonas Saal, Fiamma Berner, Christa Lichtensteiger, Nina Wyss, Annkristin Heine, Franz Georg Bauernfeind, Joerg Ellinger, Peter Brossart, Stefan Diem, Sabine Schmid, Markus Joerger, Martin Frueh, Manuel Ritter, Michael Hoelzel, Lukas Flatz, Tobias Bald
Summary: Early dynamics of C reactive protein (CRP) can serve as a predictive biomarker for response to anti-PD-1 immune checkpoint blockade (ICB) in non-small cell lung cancer (NSCLC). CRP flare-responders can predict ICB response and survival as early as 4 weeks after therapy initiation. Early CRP kinetics have no predictive value for chemoimmunotherapy or when steroids are administered concurrently.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Federica Lo Sardo, Claudio Pulito, Andrea Sacconi, Etleva Korita, Marius Sudol, Sabrina Strano, Giovanni Blandino
Summary: YAP and TAZ play important roles in non-small cell lung cancer (NSCLC) by regulating the expression of miRNAs, including miR-25, 93, and 106b. They cooperate with EZH2 to transcriptionally repress TGFBR2 and other tumor suppressor genes, promoting lung tumorigenesis. These findings suggest YAP/TAZ and EZH2 as potential therapeutic targets for NSCLC treatment.
Article
Genetics & Heredity
Xinpei Gu, Liuxi Chu, Yanlan Kang
Summary: This study identified key angiogenic factors (AFs) closely related to the development of NSCLC and constructed a novel prognostic risk model based on these factors. The model showed good discrimination and calibration, making it a valuable tool for predicting treatment prognosis in clinical practice.
FRONTIERS IN GENETICS
(2022)
Article
Biochemistry & Molecular Biology
Lisa Derosa, Bertrand Routy, Andrew Maltez Thomas, Valerio Iebba, Gerard Zalcman, Sylvie Friard, Julien Mazieres, Clarisse Audigier-Valette, Denis Moro-Sibilot, Francois Goldwasser, Carolina Alves Costa Silva, Safae Terrisse, Melodie Bonvalet, Arnaud Scherpereel, Herve Pegliasco, Corentin Richard, Francois Ghiringhelli, Arielle Elkrief, Antoine Desilets, Felix Blanc-Durand, Fabio Cumbo, Aitor Blanco, Romain Boidot, Sandy Chevrier, Romain Daillere, Guido Kroemer, Laurie Alla, Nicolas Pons, Emmanuelle Le Chatelier, Nathalie Galleron, Hugo Roume, Agathe Dubuisson, Nicole Bouchard, Meriem Messaoudene, Damien Drubay, Eric Deutsch, Fabrice Barlesi, David Planchard, Nicola Segata, Stephanie Martinez, Laurence Zitvogel, Jean-Charles Soria, Benjamin Besse
Summary: In addition to PD-L1 expression, biomarkers for predicting the response to immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer (NSCLC) are needed. This study found that fecal Akkermansia muciniphila (Akk) was associated with clinical benefit of ICI treatment in NSCLC patients, independent of PD-L1 expression and other factors. The relative abundance of Akk in the gut microbiome may serve as a potential biomarker for patient stratification.
Article
Multidisciplinary Sciences
Jasmin Sponagel, Siddhartha Devarakonda, Joshua B. Rubin, Jingqin Luo, Joseph E. Ippolito
Summary: The study found that male NSCLC cells produce more serine from glucose compared to female cells, and this higher serine biosynthesis is correlated with increased sensitivity to pemetrexed in male cells.
Article
Multidisciplinary Sciences
Clemens Hinterleitner, Jasmin Straehle, Elke Malenke, Martina Hinterleitner, Melanie Henning, Marco Seehawer, Tatjana Bilich, Jonas Heitmann, Martina Lutz, Sven Mattern, Sophia Scheuermann, Marius Horger, Stefanie Maurer, Juliane Walz, Falko Fend, Rupert Handgretinger, Christian Seitz, Bettina Weigelin, Stephan Singer, Helmut Salih, Oliver Borst, Hans-Georg Kopp, Lars Zender
Summary: This study demonstrates that platelet-derived PD-L1 can serve as a prognostic and predictive biomarker in non-small cell lung cancer patients, playing a role in tumor immune evasion and affecting T cell function. An algorithm was developed to calculate the adjusted PD-L1 payload of platelets (pPD-L1(Adj.)), which showed superior predictive ability for therapy response compared to standard histological PD-L1 quantification.
NATURE COMMUNICATIONS
(2021)
Article
Multidisciplinary Sciences
Stanley Gutiontov, William Tyler Turchan, Liam F. Spurr, Sherin J. Rouhani, Carolina Soto Chervin, George Steinhardt, Angela M. Lager, Pankhuri Wanjari, Renuka Malik, Philip P. Connell, Steven J. Chmura, Aditya Juloori, Philip C. Hoffman, Mark K. Ferguson, Jessica S. Donington, Jyoti D. Patel, Everett E. Vokes, Ralph R. Weichselbaum, Christine M. Bestvina, Jeremy P. Segal, Sean P. Pitroda
Summary: The study found that the loss of CDKN2A function is associated with poorer clinical outcomes in advanced NSCLC patients treated with ICB, even in high PD-L1 and high TMB tumors. This novel finding should be further validated and may serve as a potential therapeutic target.
SCIENTIFIC REPORTS
(2021)
Article
Cell Biology
Dan Wang, Jiangen Ao, Youwen Xiong, Xinyi Zhang, Weifang Zhang
Summary: This study for the first time reveals the mutation and dysregulation of Stress Granule Regulators in non-small cell lung cancer (NSCLC). Three subtypes of NSCLC are identified based on the expression levels of Stress Granule Regulators. The study shows different sensitivities of NSCLC subtypes to signaling inhibitors and immune therapy. Additionally, a Stress Granule Score is constructed to predict the prognosis of NSCLC.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Letter
Medicine, General & Internal
Hollis Viray, Deepa Rangachari, Daniel B. Costa
Summary: The study reported initial data of trastuzumab deruxtecan in the treatment of lung cancers with ERBB2 mutations, including patients who had previously received ineffective ERBB2 tyrosine kinase inhibitors.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Multidisciplinary Sciences
Nishanth Ulhas Nair, Patricia Greninger, Xiaohu Zhang, Adam A. Friedman, Arnaud Amzallag, Eliane Cortez, Avinash Das Sahu, Joo Sang Lee, Anahita Dastur, Regina K. Egan, Ellen Murchie, Michele Ceribelli, Giovanna S. Crowther, Erin Beck, Joseph McClanaghan, Carleen Klump-Thomas, Jessica L. Boisvert, Leah J. Damon, Kelli M. Wilson, Jeffrey Ho, Angela Tam, Crystal McKnight, Sam Michael, Zina Itkin, Mathew J. Garnett, Jeffrey A. Engelman, Daniel A. Haber, Craig J. Thomas, Eytan Ruppin, Cyril H. Benes
Summary: Combination of anti-cancer drugs is commonly used to overcome limited efficacy of single agents. Designing and testing combinations are challenging due to the heterogeneity of tumor response. Co-targeting functionally proximal genes may result in higher efficacy, offering a strategy for more efficient combinations.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Haiying Ding, Jiao Sun, Yu Song, Wenxiu Xin, Junfeng Zhu, Like Zhong, Yinbo Chen, Yiwen Zhang, Yinghui Tong, Luo Fang
Summary: The prognosis of NSCLC patients is closely related to the distance between tumor microvessels and cancer cells, with longer distances associated with poorer survival rates.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Fangfang Huang, Yushi Zheng, Xiaoling Li, Hui Luo, Lianxiang Luo
Summary: The study identified the potential prognostic value of ferroptosis-related gene AKR1C1 in non-small cell lung cancer (NSCLC). Elevated expression of AKR1C1 was associated with low levels of ferroptosis and silencing AKR1C1 inhibited cell proliferation and migration while promoting ferroptosis occurrence in NSCLC. This suggests AKR1C1 could serve as a prognostic predictor in NSCLC.
CANCER CELL INTERNATIONAL
(2021)
Article
Biotechnology & Applied Microbiology
Juanjuan Yong, Liyun Huang, Gengbiao Chen, Xiaoya Luo, Hui Chen, Lin Wang
Summary: Stabilin-2 is found to regulate cancer progression, with higher expression indicating poor prognosis in NSCLC patients. The expression of Stabilin-2 is associated with N stage and age, and it is a significant predictor for overall survival (OS) and disease-free survival (DFS) in NSCLC.
Article
Immunology
Anqi Lin, Hongman Zhang, Hui Meng, Ze Deng, Tianqi Gu, Peng Luo, Jian Zhang
Summary: This research indicates that TNFα-MT may serve as a potential clinical biomarker for predicting the efficacy and prognosis of NSCLC patients receiving ICIs. TNFα-MT is associated with high immunogenicity and infiltration of immune cells.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemical Research Methods
Martin Klammer, Klaus Godl, Andreas Tebbe, Christoph Schaab
BMC BIOINFORMATICS
(2010)
Article
Oncology
Stefan Weigand, Frank Herting, Daniela Maisel, Adam Nopora, Edgar Voss, Christoph Schaab, Martin Klammer, Andreas Tebbe
Article
Biochemistry & Molecular Biology
Michael A. D'Elia, Kathryn E. Millar, Amit P. Bhavsar, Ana M. Tomijenovic, Bernd Hutter, Christoph Schaab, Gabriel Moreno-Hagelsieb, Eric D. Brown
CHEMISTRY & BIOLOGY
(2009)
Article
Biochemical Research Methods
Sibylle Guendisch, Kathrin Grundner-Culemann, Claudia Wolff, Christina Schott, Bilge Reischauer, Manuela Machatti, Daniel Groelz, Christoph Schaab, Andreas Tebbe, Karl-Friedrich Becker
JOURNAL OF PROTEOME RESEARCH
(2013)
Article
Biochemical Research Methods
Felix S. Oppermann, Martin Klammer, Caroline Bobe, Juergen Cox, Christoph Schaab, Andreas Tebbe, Henrik Daub
JOURNAL OF PROTEOME RESEARCH
(2013)
Article
Biochemical Research Methods
Tamar Geiger, Anja Wehner, Christoph Schaab, Juergen Cox, Matthias Mann
MOLECULAR & CELLULAR PROTEOMICS
(2012)
Article
Biochemical Research Methods
Christoph Schaab, Tamar Geiger, Gabriele Stoehr, Juergen Cox, Matthias Mann
MOLECULAR & CELLULAR PROTEOMICS
(2012)
Article
Biochemical Research Methods
Gabriele Stoehr, Christoph Schaab, Johannes Graumann, Matthias Mann
MOLECULAR & CELLULAR PROTEOMICS
(2013)
Article
Biochemical Research Methods
Nina Maeusbacher, Thiemo B. Schreiber, Manuela Machatti, Christoph Schaab, Henrik Daub
Article
Oncology
Laura Conradt, Klaus Godl, Christoph Schaab, Andreas Tebbe, Stefan Eser, Sandra Diersch, Christoph W. Michalski, Joerg Kleeff, Angelika Schnieke, Roland M. Schmid, Dieter Saur, Guenter Schneider
Article
Microbiology
B Hutter, C Schaab, S Albrecht, M Borgmann, NA Brunner, C Freiberg, K Ziegelbauer, CO Rock, I Ivanov, H Loferer
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2004)
Article
Microbiology
B Hutter, C Fischer, A Jacobi, C Schaab, H Loferer
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2004)
Article
Biochemistry & Molecular Biology
AW Machl, C Schaab, I Ivanov
NUCLEIC ACIDS RESEARCH
(2002)